Syndax Pharmaceuticals (SNDX) Non-Current Deffered Revenue (2015 - 2021)

Syndax Pharmaceuticals' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $10.9 million for Q2 2021.

• In Q2 2021, Non-Current Deffered Revenue fell 12.25% year-over-year to $10.9 million; the TTM figure through Jun 2021 stood at $10.9 million (down 12.25% YoY), while the FY2020 annual figure was $11.6 million, down 11.54% from the prior year.
• Non-Current Deffered Revenue for Q2 2021 stood at $10.9 million, down from $11.2 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $16.8 million in Q4 2017, with the low at $10.9 million in Q2 2021.
• The 5-year median for Non-Current Deffered Revenue is $13.6 million (2017), against an average of $13.6 million.
• The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue gained 17.86% in 2017, then retreated 12.58% in 2018.
• Syndax Pharmaceuticals' Non-Current Deffered Revenue stood at $16.8 million in 2017, then decreased by 12.58% to $14.6 million in 2018, then fell by 10.35% to $13.1 million in 2019, then retreated by 11.54% to $11.6 million in 2020, then retreated by 6.52% to $10.9 million in 2021.
• Business Quant data shows SNDX's Non-Current Deffered Revenue at $10.9 million in Q2 2021, $11.2 million in Q1 2021, and $11.6 million in Q4 2020.